» Articles » PMID: 34945208

Headache Worsening After COVID-19 Vaccination: An Online Questionnaire-Based Study on 841 Patients with Migraine

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Dec 24
PMID 34945208
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccines have represented the breakthrough in the fight against COVID-19. Based on reported headache attacks after vaccination in randomized controlled trials, we focused on the effects of COVID-19 vaccine administration on the migraine population, using an online questionnaire published on Italian Facebook groups oriented to headache patients. We collected data about the demographics and clinical parameters of migraine severity, COVID-19 infection, vaccination, and characteristics of headaches following vaccination. Out of 841 migraine patients filling in the questionnaire, 66.47% and 60.15% patients experienced a headache attack (from 1 hour to 7 days) after the first and the second vaccine dose, respectively. The main finding concerns headaches perceived by 57.60% of patients: attacks following vaccination were referred to as more severe (50.62% of patients), long-lasting (52.80% of patients) and hardwearing (49.69% of patients) compared to the usually experienced migraine attacks. This could be related to the production of inflammatory mediators such as type Iβ interferon. Considering the high prevalence of migraine in the general population, awareness of the possibility of headaches worsening following COVID-19 vaccination in these patients may allow both patients and clinicians to face this clinical entity with conscious serenity, and to reduce the waste of resources towards inappropriate health-care.

Citing Articles

COVID-19, vaccination and migraine: Causal association or epiphenomenon?.

Jiang H, Zhang C, Meng X, Chi S, Huang D, Deng S PLoS One. 2024; 19(8):e0308151.

PMID: 39159242 PMC: 11333006. DOI: 10.1371/journal.pone.0308151.


Effects of vaccination on COVID-19 infection symptoms in multiple sclerosis patients.

Sharifi P, Rezaeimanesh N, Moradi A, Naser Moghadasi A eNeurologicalSci. 2024; 36:100511.

PMID: 38989276 PMC: 11231562. DOI: 10.1016/j.ensci.2024.100511.


Occurrence of new or more severe headaches following COVID-19 is associated with markers of microglial activation and peripheral sensitization: results from a prospective cohort study.

Ruhnau J, Blucher M, Bahlmann S, Zieme A, Vogelgesang A, Steinmetz A J Headache Pain. 2024; 25(1):101.

PMID: 38890625 PMC: 11186149. DOI: 10.1186/s10194-024-01810-6.


A Comparison of the Immunogenicity and Safety of an Additional Heterologous versus Homologous COVID-19 Vaccination among Non-Seroconverted Immunocompromised Patients after a Two-Dose Primary Series of mRNA Vaccination: A Systematic Review and....

Nangsue C, Srisurapanont K, Sudjaritruk T Vaccines (Basel). 2024; 12(5).

PMID: 38793719 PMC: 11125606. DOI: 10.3390/vaccines12050468.


A retrospective cohort study: is COVID-19 BNT162b2 mRNA vaccination a trigger factor for cluster headache?.

Turan S, Aydin S Acta Neurol Belg. 2024; 124(5):1535-1542.

PMID: 38619748 DOI: 10.1007/s13760-024-02536-7.


References
1.
Gobel C, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A . Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain Ther. 2021; 10(2):1309-1330. PMC: 8314854. DOI: 10.1007/s40122-021-00296-3. View

2.
DAmico D, La Mantia L, Rigamonti A, Usai S, Mascoli N, Milanese C . Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia. 2004; 24(11):980-4. DOI: 10.1111/j.1468-2982.2004.00790.x. View

3.
DAndrea G, Toldo M, Cananzi A, FERRO-MILONE F . Study of platelet activation in migraine: control by low doses of aspirin. Stroke. 1984; 15(2):271-5. DOI: 10.1161/01.str.15.2.271. View

4.
Deshotels M, Xia H, Sriramula S, Lazartigues E, Filipeanu C . Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014; 64(6):1368-1375. PMC: 4231883. DOI: 10.1161/HYPERTENSIONAHA.114.03743. View

5.
Kursun O, Yemisci M, van den Maagdenberg A, Karatas H . Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain. 2021; 22(1):55. PMC: 8192049. DOI: 10.1186/s10194-021-01271-1. View